How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis

Annals of Surgical Oncology

Volumn 15, Issue 2, 2008, Pages 472-477

  Reimer, Toralf ^a   Fietkau, Rainer ^a   Markmann, Susanne ^b   Stachs, Angrit ^a   Gerber, Bernd ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Klinikum Suedstadt Rostock   (Germany)

Author keywords

Axillary dissection; Breast cancer; Chemotherapy; Radiotherapy; Survival; Tumor board

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; GOSERELIN; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DECISION MAKING; MEDICAL RECORD; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; RISK ASSESSMENT; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AXILLA; BREAST TUMOR; COMORBIDITY; COMPARATIVE STUDY; DECISION MAKING; LUNG CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SEGMENTAL MASTECTOMY; STATISTICAL MODEL; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DECISION MAKING; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 40649117210     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9670-7     Document Type: Article

References (16)

1. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567-75
2. Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? Ann Surg 1997; 226:279-87
3. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol 1999; 6:109-16
4. Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol 1999; 17:1465-73
5. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17:1772-6
6. Engel J, Lebeau A, Sauer H, Hölzel D. Are we wasting our time with the sentinel technique? Fifteen reasons to stop axilla dissection. Breast 2006; 15:452-5
7. Henderson IC. Axillary surgery: clinical judgment required. J Clin Oncol 2006; 24:325-6
8. Kuehn T, Bembenek A, Decker T, Munz DL, Sautter-Bihl ML, Untch M, Wallwiener D. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005; 103:451-61
9. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16:1569-83
10. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980-91
11. Chua B, Ung O, Taylor R, Boyages J. Is information from axillary dissection relevant to patients with clinically node-negative breast cancer? Breast J 2003; 9:478-84
12. Greco M, Gennaro M, Valagussa P, et al. Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Ann Oncol 2000; 11:1137-40
13. Jackson JSH, Olivotto IA, Wai E, Grau C, Mates D, Ragaz J. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma. Cancer 2000; 88:1852-62
14. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23:2716-25
15. Wong JS, O'Neill A, Recht A, Schnitt SJ, Connolly JL, Silver B, Harris JR. The relationship between lymphatic vessel invasion, tumor size, and pathological nodal status: can we predict who can avoid a third field in the absence of axillary dissection? Int J Radiat Oncol Biol Phys 2000; 48:133-7
16. Olivotto IA, Jackson JSH, Mates D, Andersen S, Davidson W, Bryce CJ, Ragaz J. Prediction of axillary lymph node involvement of women with invasive breast carcinoma. Cancer 1998; 83:948-55